Evidence map›Paper›PMID 40873793›Full record

ArticleFrontiers in medicine2025

Case Report: Papillary renal cell carcinoma complicated by ipsilateral renal tuberculosis.

Zhong Tian, Cheng Zhu, Tingting Yang, Shicheng Chen, Zhongcong He, Guang Han, Zhouhui Chen, Neng Zhang, Bo Yu, Ni Fu

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Zhong Tian *Department of Urology, The Second Affiliated Hospital of Zunyi Medical University, Zunyi, China.
Cheng Zhu *Department of Urology, The Second Affiliated Hospital of Zunyi Medical University, Zunyi, China.
Tingting YangDepartment of Urology, The Affiliated Hospital of Zunyi Medical University, Zunyi, China.
Shicheng ChenDepartment of Urology, The Second Affiliated Hospital of Zunyi Medical University, Zunyi, China.
Zhongcong HeDepartment of Urology, The Second Affiliated Hospital of Zunyi Medical University, Zunyi, China.
Guang HanDepartment of Urology, The Second Affiliated Hospital of Zunyi Medical University, Zunyi, China.
Zhouhui ChenDepartment of Urology, The Second Affiliated Hospital of Zunyi Medical University, Zunyi, China.
Neng ZhangDepartment of Urology, The Affiliated Hospital of Zunyi Medical University, Zunyi, China.
Bo YuDepartment of Urology, The Second Affiliated Hospital of Zunyi Medical University, Zunyi, China.
Ni FuDepartment of Urology, The Second Affiliated Hospital of Zunyi Medical University, Zunyi, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Papillary renal cell carcinoma (PRCC) complicated by ipsilateral renal tuberculosis (TB) represents an exceptionally rare and complex clinical condition. Renal TB is the most common form of urogenital TB, while PRCC is the most prevalent histological subtype of non-clear cell renal cell carcinoma (RCC). In this study, we present the first reported case of PRCC complicated by ipsilateral renal TB, where the patient exhibited low back pain without hematuria. Initial imaging studies indicated a space-occupying lesion in the left kidney, raising suspicion of renal tumors. Subsequent postoperative pathology, immunohistochemical staining, and tuberculosis PCR results confirmed the diagnosis of PRCC complicated by ipsilateral renal TB.

Indexed as

papillary renal cell carcinomarenal cell carcinomarenal cell carcinoma with renal tuberculosisrenal tuberculosistumor

Identifiers

PMID40873793
PMCPMC12379642

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.